This company has been acquired
AYLA Stock Overview
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Ayala Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.50 |
| 52 Week High | US$6.77 |
| 52 Week Low | US$0.36 |
| Beta | 1.99 |
| 1 Month Change | 18.49% |
| 3 Month Change | -20.06% |
| 1 Year Change | -92.53% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -96.65% |
Recent News & Updates
Recent updates
Ayala stock rises 12% on FDA fast track status for AL102 for desmoid tumors
Sep 27Ayala Pharma rises on positive data from phase 2/3 trial of AL102 in desmoid tumors
Sep 12Here's Why Ayala Pharmaceuticals (NASDAQ:AYLA) Must Use Its Cash Wisely
Jul 28
Here's Why We're A Bit Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Mar 19Will Ayala Pharmaceuticals (NASDAQ:AYLA) Spend Its Cash Wisely?
Sep 11We Think Ayala Pharmaceuticals (NASDAQ:AYLA) Needs To Drive Business Growth Carefully
Jun 04Here's Why We're Not Too Worried About Ayala Pharmaceuticals' (NASDAQ:AYLA) Cash Burn Situation
Feb 19Ayala Pharmaceuticals to proceed with Phase 2/3 stage of cancer study
Jan 04Need To Know: Analysts Are Much More Bullish On Ayala Pharmaceuticals, Inc. (NASDAQ:AYLA) Revenues
Nov 20
Shareholder Returns
| AYLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.2% | -2.8% | -1.7% |
| 1Y | -92.5% | -0.2% | 22.4% |
Return vs Industry: AYLA underperformed the US Biotechs industry which returned 7.2% over the past year.
Return vs Market: AYLA underperformed the US Market which returned -11.7% over the past year.
Price Volatility
| AYLA volatility | |
|---|---|
| AYLA Average Weekly Movement | 13.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AYLA's share price has been volatile over the past 3 months.
Volatility Over Time: AYLA's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 35 | Roni Mamluk | www.ayalapharma.com |
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company’s lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors.
Ayala Pharmaceuticals, Inc. Fundamentals Summary
| AYLA fundamental statistics | |
|---|---|
| Market cap | US$7.20m |
| Earnings (TTM) | -US$38.47m |
| Revenue (TTM) | US$1.73m |
4.2x
P/S Ratio-0.2x
P/E RatioIs AYLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AYLA income statement (TTM) | |
|---|---|
| Revenue | US$1.73m |
| Cost of Revenue | US$1.64m |
| Gross Profit | US$90.00k |
| Other Expenses | US$38.56m |
| Earnings | -US$38.47m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.69 |
| Gross Margin | 5.19% |
| Net Profit Margin | -2,220.08% |
| Debt/Equity Ratio | 0% |
How did AYLA perform over the long term?
See historical performance and comparison